Rheumatology Research Group, University of Birmingham, Edgbaston, Birmingham, UK.
Lupus. 2010 Mar;19(3):327-9. doi: 10.1177/0961203309347332. Epub 2009 Nov 9.
Severe retinal vasculitis is a rare, but potentially blinding, complication of patients with systemic lupus erythematosus (SLE). We describe here the first reported case of treating severe bilateral SLE-associated retinal vasculitis with the anti-CD20 monoclonal antibody rituximab, a drug which has established its role in rheumatoid arthritis and has shown promise in case series for the treatment of severe SLE that is unresponsive to other therapies. This case suggests that rituximab-induced B-cell depletion may provide an important new therapeutic option for refractory cases of this devastating ocular complication.
严重的视网膜血管炎是系统性红斑狼疮（SLE）患者罕见但潜在致盲的并发症。我们在此描述首例使用抗 CD20 单克隆抗体利妥昔单抗治疗严重双侧与 SLE 相关的视网膜血管炎的病例，该药已在类风湿关节炎中确立了其地位，并在一些对其他治疗反应不佳的严重 SLE 病例的系列研究中显示出前景。该病例提示利妥昔单抗诱导的 B 细胞耗竭可能为这种破坏性眼部并发症的难治性病例提供了一个重要的新治疗选择。
